semaglutide regain weight Patients rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost Stopping GLP-1 Drugs Triggers Weight

McElroy SL et al

You'll have scheduled check-ins with your provider to review how you're responding, adjust dosing if needed, and address any barriers to progress

glucagon suppression, lowering hepatic glucose output Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses) Adiposity/Energy Intake : Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure Biological Activity Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids) Storage Refrigerate once reconstituted

Report any side effects to the FDAs MedWatch